CatalystMarker
← board

PLRZ

distress 6/10 · elevated risk
$14.27-1%today-17% from 52w high
polyrizon-biotech.com2 employeesFounded 2005Ra'anana, IsraelBiotechnology
Revenue
pre-revenue
Liquidity
$1M
Runway
0.3 yrs
Shares 1y
0%

Price & events

-9.0% over 6M
$10.75$13.96$17.17Jan 26Apr 26Jul 26245kdilution: EFFECT shelf_effective (2026-05-04)dilution: F-1/A shelf_registration (2026-04-30)dilution: F-1 shelf_registration (2026-04-23)dilution: 424B5 offering (2026-04-08)
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
+9.7%
1W
+20.9%
1M
-3.5%
3M
-10.5%
6M
+26.5%
1Y
2Y
5Y
-99.4%
All

Overview

Market Cap
$22.94M
Volume
6.87K
52 Week Range
$3.13 – $17.17
Total Shares
1.61M
Float Shares
1.42M
Short %
1.97%
% Held by Insiders
0.83%
% Held by Institutions
7.13%
RVOL
0.17x

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 1,608,266 · 2 offerings/1y · 0 PIPEs
  • 2026-05-04EFFECTshelf_effective
  • 2026-04-30F-1/Ashelf_registration
  • 2026-04-23F-1shelf_registration
  • 2026-04-08424B5offering
  • 2025-12-05424B5offering
  • 2025-12-03EFFECTshelf_effective
  • 2025-11-07F-3shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.